PCL201H1 Lecture Notes - Lecture 28: Cetuximab, Etanercept, Pharmacoeconomics
14 Sep 2016
School
Department
Course
Professor
Document Summary
Health expenditure varies across oecd countries: us spending the highest, 2. 5x the oecd average, canada also one of the top, hospitals taking the biggest share of expenses at 28. 4% Drug spending in canada: billion in 2008, with prescription drugs accounting for 84, /year/canadian, us at highest level of total per capita on drugs, canada 2nd. Metastatic colorectal cancer is the leading case of cancer. Tumor in colon, rectum, and appendix, spreads to liver. Cetuximab, a egfr inhibitor, is the first drug to show efficacy to this type of cancer. Extends life from 4. 6 months to 6. 1 months. Rheumatoid arthritis is an auto-immune disease affecting 1% of the population. Average onset at 35 years of age. Etanercept is a tumor necrosis factor-alpha inhibitor to improve quality of life. ,000/year for lifetime: many factors affecting the choice: clinical outcome, cost-benefit, type of disease, patient, etc, national framework for cost-effectiveness determination. Drug reimbursement-economic studies/budget impact = value of drug.
